{
    "nct_id": "NCT06426303",
    "official_title": "Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder",
    "inclusion_criteria": "* 18-60 years old\n* Veteran enrolled in VHA healthcare\n\nAlcohol Group:\n\n* must meet diagnosis for recent alcohol-use disorder (DSM-V)\n* willing to return for follow-up visits and can participate for 12-weeks\n\nControl Group:\n\n* must not meet DSM-V criteria for a use disorder other than nicotine\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 60 Years",
    "exclusion_criteria": "* Clinically significant neurological, endocrine, hepatic, or systemic disease that would compromise safe participation or confound outcomes\n* Left-handedness\n* Axis-1 psychiatric diagnoses other than anxiety, depression or post-traumatic stress disorder\n* Recreational or prescriptive use of psychotropic medications\n* Recreational or prescriptive use of opioid medications or have a past or current history of abuse or dependence on opioids\n* MRI contraindications (e.g. metal in body)\n* Positive urine drug screen, except for nicotine and marijuana, on test days\n* Women who are pregnant or breastfeeding\n* Participants on hormonal therapy or treatments other than pregnancy contraceptives\n* Autoimmune or neurodegenerative diseases that present with neuroinflammation (multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's, Parkinson's)\n* Current participation in an investigational drug study\n* Alcohol group: < 5 days and > 3 weeks of abstinence from alcohol\n* Alcohol group: Liver disease requiring medication or medical treatment, and/or aspartate or alanine aminotransferase levels greater than 3 times the upper limit of normal, gastrointestinal or renal disease that would significantly impair absorption, metabolism or excretion of study drug, or require medical treatment.\n* Non-english speaker",
    "miscellaneous_criteria": ""
}